253 related articles for article (PubMed ID: 26010308)
1. The Presence of Genetic Mutations at Key Loci Predicts Progression to Esophageal Adenocarcinoma in Barrett's Esophagus.
Eluri S; Brugge WR; Daglilar ES; Jackson SA; Styn MA; Callenberg KM; Welch DC; Barr TM; Duits LC; Bergman JJ; Shaheen NJ
Am J Gastroenterol; 2015 Jun; 110(6):828-34. PubMed ID: 26010308
[TBL] [Abstract][Full Text] [Related]
2. Validation of a biomarker panel in Barrett's esophagus to predict progression to esophageal adenocarcinoma.
Eluri S; Klaver E; Duits LC; Jackson SA; Bergman JJ; Shaheen NJ
Dis Esophagus; 2018 Nov; 31(11):. PubMed ID: 29635420
[TBL] [Abstract][Full Text] [Related]
3. Assessment of mutational load in biopsy tissue provides additional information about genomic instability to histological classifications of Barrett's esophagus.
Khara HS; Jackson SA; Nair S; Deftereos G; Patel S; Silverman JF; Ellsworth E; Sumner C; Corcoran B; Smith DM; Finkelstein S; Gross SA
J Gastrointest Cancer; 2014 Jun; 45(2):137-45. PubMed ID: 24402860
[TBL] [Abstract][Full Text] [Related]
4. Loss of heterozygosity on chromosome 17p predicts neoplastic progression in Barrett's esophagus.
Dolan K; Morris AI; Gosney JR; Field JK; Sutton R
J Gastroenterol Hepatol; 2003 Jun; 18(6):683-9. PubMed ID: 12753151
[TBL] [Abstract][Full Text] [Related]
5. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.
Anaparthy R; Gaddam S; Kanakadandi V; Alsop BR; Gupta N; Higbee AD; Wani SB; Singh M; Rastogi A; Bansal A; Cash BD; Young PE; Lieberman DA; Falk GW; Vargo JJ; Thota P; Sampliner RE; Sharma P
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1430-6. PubMed ID: 23707463
[TBL] [Abstract][Full Text] [Related]
6. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus.
Wani S; Falk GW; Post J; Yerian L; Hall M; Wang A; Gupta N; Gaddam S; Singh M; Singh V; Chuang KY; Boolchand V; Gavini H; Kuczynski J; Sud P; Bansal A; Rastogi A; Mathur SC; Young P; Cash B; Goldblum J; Lieberman DA; Sampliner RE; Sharma P
Gastroenterology; 2011 Oct; 141(4):1179-86, 1186.e1. PubMed ID: 21723218
[TBL] [Abstract][Full Text] [Related]
8. Risk stratification of patients with barrett's esophagus and low-grade dysplasia or indefinite for dysplasia.
Thota PN; Lee HJ; Goldblum JR; Liu X; Sanaka MR; Gohel T; Kanadiya M; Lopez R
Clin Gastroenterol Hepatol; 2015 Mar; 13(3):459-465.e1. PubMed ID: 25102445
[TBL] [Abstract][Full Text] [Related]
9. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.
Werther M; Saure C; Pahl R; Schorr F; Rüschoff J; Alles JU; Heinmöller E
Pathol Res Pract; 2008; 204(5):285-94. PubMed ID: 18337019
[TBL] [Abstract][Full Text] [Related]
10. Detection of Mutations in Barrett's Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma.
Stachler MD; Camarda ND; Deitrick C; Kim A; Agoston AT; Odze RD; Hornick JL; Nag A; Thorner AR; Ducar M; Noffsinger A; Lash RH; Redston M; Carter SL; Davison JM; Bass AJ
Gastroenterology; 2018 Jul; 155(1):156-167. PubMed ID: 29608884
[TBL] [Abstract][Full Text] [Related]
11. DNA abnormalities as marker of risk for progression of Barrett's esophagus to adenocarcinoma: image cytometric DNA analysis in formalin-fixed tissues.
Fang M; Lew E; Klein M; Sebo T; Su Y; Goyal R
Am J Gastroenterol; 2004 Oct; 99(10):1887-94. PubMed ID: 15447746
[TBL] [Abstract][Full Text] [Related]
12. A biomarker panel predicts progression of Barrett's esophagus to esophageal adenocarcinoma.
Duits LC; Lao-Sirieix P; Wolf WA; O'Donovan M; Galeano-Dalmau N; Meijer SL; Offerhaus GJA; Redman J; Crawte J; Zeki S; Pouw RE; Chak A; Shaheen NJ; Bergman JJGHM; Fitzgerald RC
Dis Esophagus; 2019 Jan; 32(1):. PubMed ID: 30496496
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Mutational Testing of Preneoplastic Barrett's Mucosa by Next-Generation Sequencing of Formalin-Fixed, Paraffin-Embedded Endoscopic Samples for Detection of Concurrent Dysplasia and Adenocarcinoma in Barrett's Esophagus.
Del Portillo A; Lagana SM; Yao Y; Uehara T; Jhala N; Ganguly T; Nagy P; Gutierrez J; Luna A; Abrams J; Liu Y; Brand R; Sepulveda JL; Falk GW; Sepulveda AR
J Mol Diagn; 2015 Jul; 17(4):412-9. PubMed ID: 26068095
[TBL] [Abstract][Full Text] [Related]
14. Increasing diagnostic accuracy to grade dysplasia in Barrett's esophagus using an immunohistochemical panel for CDX2, p120ctn, c-Myc and Jagged1.
Karamchandani DM; Lehman HL; Ohanessian SE; Massé J; Welsh PA; Odze RD; Goldblum JR; Berg AS; Stairs DB
Diagn Pathol; 2016 Feb; 11():23. PubMed ID: 26926447
[TBL] [Abstract][Full Text] [Related]
15. [Polymorphism/loss of heterozygosity of APC gene in GERD-Barrett's metaplasia-dysplasia-adenocarcinoma sequence].
Mokrowiecka A; Wierzchniewska-Ławska A; Smolarz B; Romanowicz-Makowska H; Malecka-Panas E
Pol Merkur Lekarski; 2009 May; 26(155):385-9. PubMed ID: 19606680
[TBL] [Abstract][Full Text] [Related]
16. Correlation of the presence and extent of loss of heterozygosity mutations with histological classifications of Barrett's esophagus.
Ellsworth E; Jackson SA; Thakkar SJ; Smith DM; Finkelstein S
BMC Gastroenterol; 2012 Dec; 12():181. PubMed ID: 23270334
[TBL] [Abstract][Full Text] [Related]
17. SOX2 as a novel marker to predict neoplastic progression in Barrett's esophagus.
van Olphen S; Biermann K; Spaander MC; Kastelein F; Steyerberg EW; Stoop HA; Bruno MJ; Looijenga LH
Am J Gastroenterol; 2015 Oct; 110(10):1420-8. PubMed ID: 26323187
[TBL] [Abstract][Full Text] [Related]
18. Risk for esophageal neoplasia in Barrett's esophagus patients with mucosal changes indefinite for dysplasia.
Horvath B; Singh P; Xie H; Thota PN; Allende DS; Pai RK; Patil DT; Plesec TP; Goldblum JR; Liu X
J Gastroenterol Hepatol; 2015 Feb; 30(2):262-7. PubMed ID: 25087917
[TBL] [Abstract][Full Text] [Related]
19. LOH at the sites of the DCC, APC, and TP53 tumor suppressor genes occurs in Barrett's metaplasia and dysplasia adjacent to adenocarcinoma of the esophagus.
Dolan K; Garde J; Walker SJ; Sutton R; Gosney J; Field JK
Hum Pathol; 1999 Dec; 30(12):1508-14. PubMed ID: 10667431
[TBL] [Abstract][Full Text] [Related]
20. Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study.
Sikkema M; Looman CW; Steyerberg EW; Kerkhof M; Kastelein F; van Dekken H; van Vuuren AJ; Bode WA; van der Valk H; Ouwendijk RJ; Giard R; Lesterhuis W; Heinhuis R; Klinkenberg EC; Meijer GA; ter Borg F; Arends JW; Kolkman JJ; van Baarlen J; de Vries RA; Mulder AH; van Tilburg AJ; Offerhaus GJ; ten Kate FJ; Kusters JG; Kuipers EJ; Siersema PD
Am J Gastroenterol; 2011 Jul; 106(7):1231-8. PubMed ID: 21577245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
